- Home
- CHRS vs OPFI Comparison
CHRS vs OPFI Comparison
Compare CHRS & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- OPFI
- Stock Information
- Founded
- CHRS 2010
- OPFI 2009
- Country
- CHRS United States
- OPFI United States
- Employees
- CHRS 235
- OPFI N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- OPFI Finance: Consumer Services
- Sector
- CHRS Health Care
- OPFI Finance
- Exchange
- CHRS Nasdaq
- OPFI Nasdaq
- Market Cap
- CHRS 134.4M
- OPFI 290.9M
- IPO Year
- CHRS 2014
- OPFI N/A
- Fundamental
- Price
- CHRS $1.16
- OPFI $15.03
- Analyst Decision
- CHRS Strong Buy
- OPFI Buy
- Analyst Count
- CHRS 4
- OPFI 2
- Target Price
- CHRS $5.38
- OPFI $7.50
- AVG Volume (30 Days)
- CHRS 2.4M
- OPFI 2.5M
- Earning Date
- CHRS 03-12-2025
- OPFI 03-06-2025
- Dividend Yield
- CHRS N/A
- OPFI 0.80%
- EPS Growth
- CHRS N/A
- OPFI 775.86
- EPS
- CHRS N/A
- OPFI 0.38
- Revenue
- CHRS $304,340,000.00
- OPFI $260,661,000.00
- Revenue This Year
- CHRS $2.47
- OPFI N/A
- Revenue Next Year
- CHRS N/A
- OPFI $6.51
- P/E Ratio
- CHRS N/A
- OPFI $39.68
- Revenue Growth
- CHRS 44.19
- OPFI 23.85
- 52 Week Low
- CHRS $0.66
- OPFI $2.35
- 52 Week High
- CHRS $2.87
- OPFI $15.13
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- OPFI 76.48
- Support Level
- CHRS $1.03
- OPFI $11.21
- Resistance Level
- CHRS $1.39
- OPFI $14.85
- Average True Range (ATR)
- CHRS 0.14
- OPFI 1.17
- MACD
- CHRS -0.03
- OPFI 0.17
- Stochastic Oscillator
- CHRS 14.04
- OPFI 77.48
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.